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Interpretive Summary: 1 
 Long-term elevation of beta-hydroxybutyrate in dairy cows through 2 
infusion: effects on feed intake, milk production, and metabolism. By Zarrin et 3 
al. Effects of an induced hyperketonemia for 48 hours on metabolic variables in plasma and 4 
liver of mid-lactating dairy cows were studied. Na-DL-β-OH-butyrate was infused i.v. to 5 
obtain plasma beta-hydroxybutyrate (BHBA) concentration above 1.5 mmol/L comparable to 6 
a spontaneous hyperketonemia but not caused by a lack of energy and glucose such as in early 7 
lactation. Milk yield and feed intake did not change during BHBA infusion. Plasma glucose 8 
concentration decreased during the infusion. Declined glucose concentration could not be 9 
explained by alterations of insulin or enzymes related to gluconeogenesis, but is likely 10 
functionally related to the observed decrease of plasma glucagon concentration.  11 
HYPERKETONEMIA AFFECTS METABOLISM IN DAIRY COWS 12 
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 32 
ABSTRACT 33 
Elevation of ketone bodies in dairy cows frequently occurs in early lactation usually 34 
concomitantly with a lack of energy and glucose. The objective of the present study was to 35 
induce an elevated plasma beta-hydroxybutyrate (BHBA) concentration over 48 hours in mid 36 
lactating dairy cows, i.e. during a period of positive energy balance and normal glucose 37 
plasma concentrations. Effects of the BHBA infusion on feed intake, metabolism, and 38 
performance were investigated. Thirteen cows were randomly assigned to one of two infusion 39 
groups, including an intravenous infusion with Na-DL-β-OH-butyrate (1.7 mol/L) to achieve 40 
a plasma concentration of 1.5 to 2.0 mmol/L of BHBA (HyperB, n=5), or an infusion of 0.9 % 41 
saline solution (control, n=8). Blood was sampled before and hourly during the 48 h of 42 
infusion. In liver, mRNA transcripts related to gluconeogenesis (pyruvate carboxylase (PC), 43 
glucose 6-phosphatase (G6PC), mitochondrial phosphoenolpyruvate carboxykinase 44 
(PEPCKm)), Phosphofructokinase (PFKL), pyruvatedehydrogenase complex, and fatty acid 45 
synthesis (acetyl-CoA carboxylase (ACoAC), fatty acid synthase (FASN)) were measured by 46 
real-time RT-PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ubiquitin were 47 
used as housekeeping genes. Changes (difference between before and after 48h infusion) 48 
during the infusion period were evaluated by analysis of variance with treatment as fixed 49 
effect, and area under the curve (AUC) of variables was calculated on the second day of 50 
experiment. The plasma BHBA concentration in HyperB cows was 1.74 ± 0.02 mmol/L 51 
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(mean ± SE) compared with 0.59 ± 0.02 mmol/L for control cows. The change in feed intake, 52 
milk yield and energy corrected milk (ECM) did not differ between the two experimental 53 
groups. Infusion of BHBA reduced the plasma glucose concentration (3.47 ± 0.11 mmol/L) in 54 
HyperB compared with control cows (4.11 ± 0.08 mmol/L). Plasma glucagon concentration in 55 
HyperB was lower than the control group. All other variables measured in plasma were not 56 
affected by treatment. In the liver, changes in mRNA abundance for the selected genes were 57 
similar between two groups. Results demonstrate that intravenous infusion of BHBA 58 
decreased plasma glucose concentration in dairy cows but this decrease could not be 59 
explained by alterations in insulin concentrations or key enzymes related to gluconeogenesis. 60 
Declined glucose concentration is likely functionally related to decreased plasma glucagon 61 
concentration. 62 
Key words: dairy cow, ketone bodies, glucose, beta-hydroxybutyrate, metabolism 63 
 64 
INTRODUCTION 65 
High yielding dairy cows need a lot of energy and nutrients for maintenance and milk 66 
synthesis in particular during peak lactation. Despite of increased feed intake in the early 67 
lactation (Agenäs et al., 2003) after the periparturient nadir, this adaptation cannot cover the 68 
requirements during this period. Typical metabolic changes during this period of negative 69 
energy balance are low plasma concentrations of glucose, and high concentrations of plasma 70 
non-esterified fatty acid (NEFA) and subsequently elevation of ketone bodies (van Dorland et 71 
al., 2009; Gross et al., 2011). Although ketone bodies can be used as an alternative fuel for 72 
some tissues such as brain and heart (Laffel, 1999; Veech, 2004), kidney (Weidemann and 73 
Krebs, 1969), skeletal muscles (Ruderman and Goodman, 1973) and lactating mammary 74 
gland (Shaw, 1943), the utilization of ketone bodies is limited. Unused ketone bodies 75 
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concentration increase tremendously in blood (Duffield et al., 2009). This elevation of ketone 76 
bodies in blood causes reduced feed intake and increases the risk of clinical ketosis (CK), 77 
displaced abomasums (DA), metritis and subsequent decrease of milk production (Duffield et 78 
al, 2009). The mostly used method to detect of subclinical ketosis is the measurement of 79 
BHBA in serum or plasma (Duffield, 2000; Herdt, 2000). In ruminants, BHBA is the major 80 
ketone body found in circulation (Bergman, 1971). Ospina et al (2010) suggested a threshold 81 
value of 1200 µmol/L to distinguish between normal cows and subclinical ketotic cows. 82 
Subcutaneous BHBA infusion in rats (Langhans et al., 1983; Moor et al., 1976), 83 
intraperitoneal BHBA infusion in goats (Rossi et al., 2000), and intracerebroventricular 84 
BHBA infusion in dairy cows (Kuhla et al., 2011) lead to inhibited feed intake in these 85 
animals. Intravenous BHBA infusion lead to decreased plasma concentration of glucose in 86 
dogs (Madison et al., 1964), pigs (Müller et al., 1984), and ewes (Schlumbohm and Harmeyer, 87 
2003, 2004). The reason of declined glucose during the infusion of BHBA remained unclear, 88 
but authors suggested that infusion of BHBA induced hypoglycemia through direct or indirect 89 
inhibition of gluconeogenesis or by change in insulin concentration in pig and sheep (Müller 90 
et al., 1984; Schlumbohm and Harmeyer, 2004). This mechanism has not yet been 91 
investigated in dairy cows. Our objective was to induce an elevated plasma BHBA 92 
concentration over 48 hours and to investigate its effects on feed intake, performance, and 93 
metabolism in the dairy cow. More specifically, this study was carried out to confirm that also 94 
in the dairy cow, like in sheep and pig, elevated plasma BHBA concentration affects plasma 95 
glucose concentration, and to investigate the underlying mechanisms.  96 
 97 
MATERIAL AND METHODS 98 
Animals and Management  99 
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The present trials followed the Swiss Law on Animal Protection and were permitted by the 100 
Committee of Animal Experiments of the Canton Fribourg, Switzerland. The study was 101 
carried out with 13 diestrus Holstein dairy cows with a parity of 3.5 ± 0.10, at 28 ± 0.3 102 
(MEAN ± SD) weeks in milk. Cows in later lactation were selected to allow the investigation 103 
of the specific effect of BHBA infusion without influences of the characteristic endocrine and 104 
metabolic changes during the transition period. The cows were healthy at the start of the 105 
experiment which was confirmed by a routine blood glutaraldehyde coagulation test 106 
(Sandholm, 1976), and by measuring milk somatic cell count (DeLaval cell counter DCC, 107 
Switzerland), which had to be less than 150,000 cells/mL in all four quarters.  108 
Two weeks before the start of the experiment, animals were allowed to adapt to tie stall 109 
housing and to the experimental feeding conditions. Animals were fed ad libitum with hay. In 110 
addition, cows were fed a protein- and energy- rich concentrate (Barley 23.5%, Oats 14.0%, 111 
Wheat bran 20.0%, Expeller soybean 17.0%, Linseed meal 15.0%, Salt livestock 0.6%, 112 
Carbonate of lime 2.2%, KAF premix 0.4%, Molasses 4.0%, and Alikon 3.0%) twice daily 113 
according to each cow’s individual extra energy requirement for milk production, and once 114 
daily 50 g of minerals. Water was available ad libitum. Milking was performed twice daily at 115 
0530 h and 1600 h. 116 
 117 
Experimental design and treatments 118 
The thirteen cows were randomly assigned to one of two infusion treatments. The treatments 119 
included an infusion with BHBA (HyperB, n=5) to obtain a plasma BHBA concentration 120 
between 1.5 to 2.0 mmol/L. The control treatment (n=8) included an infusion with a 0.9 % 121 
saline solution (NaCl, 20 mL/h). One day before the infusions started, cows were fitted with 122 
indwelling intravenous catheters (Cavafix® Certo® Splittocan®, B. Braun Melsung AG, 123 
Germany) with a length of 32 cm and a diameter of 16 G in both jugular veins. The infusions 124 
through one of the catheters started at 9:00 am and continued until 09:00 am two days later. 125 
6 
 
The initial infusion rate (8.5 ± 0.6 µmol/kg/min) was determined on the basis of the body 126 
weight of each animal and the molarity of the solution followed by instant continued 127 
adjustments throughout the 48 h to maintain a plasma BHBA concentration between 1.5 to 2.0 128 
mmol/L by a peristaltic pump (Perpex Jubile pump, H. J. Guldener, Zürich, Switzerland). 129 
During the first two hours of BHBA infusion, the blood samples were taken every 15 min to 130 
measure the plasma BHBA concentration and adjust the BHBA infusion rate to reach the 131 
plasma BHBA concentration between 1.5 and 2.0 mmol/L. 132 
The control cows were treated with 0.9 % saline solution at an infusion rate of 20 mL/h 133 
administered using an automatic pump (Perfuser®, B. Braun Melsung AG, Germany).  134 
 135 
Preparation of the BHBA solution 136 
To achieve a 1.7 M BHBA solution 279.053 g of DL-Beta-hydroxybutyric acid sodium salt 137 
(Sigma-Aldrich, H6501) was dissolved in bidistilled water to reach an amount of 1.0 L 138 
followed by homogenization using a rotor mixer during 10-20min. The pH of the solution was 139 
adjusted with HCl to 7.4 and sterilized at 1 bar and 131ºC for 50 min. The solution was 140 
filtered through a 0.2µm ø filter (Millipore Express® PLUS Membrane 45 mm, Millipore, 141 
China) and stored at 4°C until infusion.  142 
 143 
Data collection and sampling 144 
Feed and milk samples. The individual intake of hay was recorded daily for each cow by 145 
weighing the amount given and subtracting it by the remainder of hay found the next 146 
morning. The milk yield was recorded for each cow individually at every milking during the 147 
adaptation and experimental period. Proportional milk samples were taken during milking in 148 
the afternoon and in the morning before the start of the experimental infusions. The milk 149 
sampling was repeated in the afternoon of day two (32 h after the start of infusion), and at the 150 
morning milking at the end of experiment.  151 
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 152 
Blood samples. One week before the experiment, and immediately before the start of the 153 
experimental infusions on day 1, reference blood samples of each cow were taken from a 154 
jugular vein via vacuum tubes containing tri-potassium-EDTA at 0730 h, after milking and 155 
before feeding. The tubes were kept on wet ice until they were centrifuged for 20 minutes at 156 
3000 x g, and the plasma was obtained. Until the samples were analyzed for concentrations 157 
and activities of plasma variables, the plasma was frozen at -20 °C. After analysis, the mean 158 
value of these samples was calculated and used as reference concentration in the statistical 159 
evaluation. During the experimental infusions blood samples were obtained from the 160 
contralateral jugular catheter, which was not used for the infusion, by using tubes containing 161 
tri-potassium-EDTA. The collected blood samples were partly analyzed immediately for 162 
BHBA concentration (described under laboratory procedures) as a basis for adjustments of the 163 
infusion rate, or were handled similarly as the reference samples.  164 
 165 
Liver biopsies. One week before the infusions and 48 h after the start of the infusions, 166 
following the blood sampling, at around 0800 h, a liver biopsy was taken. Liver tissue (60 to 167 
100 mg) was obtained under local anesthesia with 10 mL Lidocain 2% (Streuli Pharma AG, 168 
Uznach) by blind liver puncture with a 14 G and 150 mm or 200 mm long biopsy needle (Tru-169 
Cut, Provet AG, Lyssach, Switzerland). The samples were placed directly into RNA 170 
stabilization reagent (RNAlater
®
, Ambion, Applied Biosysthems, Austin, TX), kept at +5 °C 171 
for 24 hours and thereafter stored at –80 °C until RNA extraction.  172 
 173 
Laboratory procedures 174 
Feed and milk. The nutritional composition of hay (DM content, 890g/kg of fresh matter 175 
(FM); on DM basis, consisting of 153 g of CP/kg, 235.0 g of Crude fiber/kg, and 5.7 MJ of 176 
NEL/kg) and concentrate (DM content, 881 g/kg of FM; on DM basis, consisting of 217 g of 177 
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CP/kg, 73.9 g of Crude fiber/kg, and 7.6 MJ of NEL/kg) were determined by using routine 178 
analyses as described by van Dorland et al. (2009). The nutritive energy balance was 179 
calculated as the difference between the energy intake, and the energy output (NEL, 180 
requirements for maintenance and milk production, determined from tabulated values and 181 
recommended equations according as to van Dorland et al. (2009)).  182 
Milk samples were analyzed at the laboratory of the Holstein Association of Switzerland, 183 
Grangeneuve, Switzerland, for their content of fat, protein, lactose and urea (CombiFoss 184 
6000, Gerber Instrument AG, Effretikon, Switzerland). The ECM was calculated based on 185 
Sjaunja et al. (1991), using the formula: ECM (kg/d) = [(0.038 × Fat (g/kg) + 0.024 × Protein 186 
(g/kg) + 0.017 × Lactose (g/kg)) × Milk Yield (kg/d)] / 3.14 187 
 188 
Blood plasma. Plasma metabolites were measured enzymatically with an automated analyzer 189 
(Cobas Mira 2, Hoffmann-La Roche, Basle, Switzerland) by the use of commercial kits as 190 
described by van Dorland et al. (2009) and Kreipe et al. (2011). Plasma insulin and insulin-191 
like growth factor-1 (IGF-1) were measured by RIA as described by Vicari et al. (2008) and 192 
total cortisol was measured by RIA as described by Blum et al. (1985). Plasma glucagon 193 
concentration was measured by using a RIA kit (cat. # GL-32K, MILLIPORE, Zug, 194 
Switzerland). 195 
 196 
Liver tissue. Total mRNA was extracted from liver samples using peqGOLD TriFast™ 197 
(PEQLAB Biotechnologie GmbH, Erlangen, Germany) according to manufacturer’s protocol, 198 
and afterwards quantity and purity were
 
determined by absorbance at 260 nm and 280 nm 199 
using a NanoDrop ND-2000
 
spectrophotometer (NanoDrop Technologies Inc., Wilmington, 200 
DE). Subsequently, one μg of total mRNA was reverse transcribed with 200 U Moleney 201 
Murine Leukemia Virus Reverse Transcriptase RNAase H Minus, Point Mutant (Promega 202 
Corporation, Madison, WI) using 100 pmol random hexamer primers (Invitrogen, Leek, The 203 
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Netherlands). A master mix containing the following components was prepared: 0.8 μL PCR 204 
water, 1.0 μL forward primer (5 pmol), 1.0 μL reverse primer (5 pmol), 5.2 μL 2x SensiMix 205 
plus SYBR-Green (1 mM MgCl2). The selected and measured genes encoding for hepatic 206 
enzymes involved in gluconeogensis, glycolysis, fatty acid oxidation, citrate synthase, fatty 207 
acid and triglyceride synthesis, cholesterol synthesis, pyruvate dehydrogenase complex, and 208 
ketogensis, are shown in Table 1. The primer sequences for PC and PEPCKm were according 209 
to Hammon et al. (2003), FASN, acyl-CoA synthetase long-chain (ASCL), carnitine 210 
palmitoyltransferase 1A (CPT1A), and citrate synthase (CS) were according to van Dorland 211 
et al. (2009), ACoC, carnitine palmitoyltransferase 2 (CPT2), G6PC, and 3- hydroxyl-3 – 212 
methylglutaryl-coenzyme A synthase 1 (HMGCS1), according to Graber et al. (2010). 213 
Lactate dehydrogenase A (LDHA), lactate dehydrogenase B (LDHB), PFKL, 214 
dihydrolipoamide branched chain transacylase E2 (DBT), dihydrolipoamide dehydrogenase 215 
(DLD), pyruvatedehydrogenase (lipomide) alpha 1 (PDHA1), glucagon receptor (GCGR), 216 
glycogen synthase 2 (GYS2), and protein kinase, AMP- activated alpha 1 (PRKAA1) primers 217 
were designed to amplify cDNA. 218 
The PCR quantification was performed by using a Rotor-Gene™ 6000 (Corbett Research, 219 
Sydney, Australia), using the software version 1.7.40. Fluorescence take off was calculated 220 
with the “threshold” program option. Eight μL of master-mix and two μL sample volume, 221 
containing 20 ng of cDNA, were used. The following three-step PCR program was 222 
performed: denaturation for 10 min at 95 °C, 40 cycles of amplification (each consisting of 15 223 
s at 95 °C, the primer-specific annealing temperature for 30 s (Graber et al., 2010; Pfaffl et al., 224 
2002), and extension at 72 °C for 20 s and quantification of fluorescence, and finally a 225 
melting curve program (60 to 95 °C). The mRNA levels were calculated relative to the mean 226 
expression level of the housekeeping genes GAPDH and ubiquitin, which were stable across 227 
time points as described by Kreipe et al (2011). 228 
 229 
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Statistical analysis 230 
Prior to data analysis, for each variable (gene expression, plasma metabolites, feed intake, 231 
milk yield, and ECM), the change (delta) was calculated by subtracting the value measured 232 
after the infusion treatments from the value measured before the infusion treatments. The 233 
delta for each variable (difference between before and after 48h infusion) was statistically 234 
evaluated using the general linear models (GLM) procedure of SAS (SAS Institute Inc., Cary, 235 
NC, USA, 2002-2008, Release 9.2), including treatment (BHBA or NaCl) as fixed effect. 236 
Differences between means were determined by the Tukey test. In addition, means of delta 237 
values obtained within each treatment were tested for their difference from “0”. Furthermore, 238 
blood plasma variables, the area under the curve (AUC) was calculated for day 2 (d2) of the 239 
treatments, and subsequently assessed statistically with the model as described above. Data 240 
obtained prior to the treatment were included as covariate in the model to compensate for 241 
initial differences between individuals. 242 
Data are presented as means ± SEM and differences were considered significant if P < 0.05, 243 
and as a trend if P < 0.10. 244 
 245 
RESULTS 246 
Infusion rates and plasma concentrations of BHBA 247 
The mean infusion rate of BHBA over 48 h was 8.5 ± 0.6 µmol/kg/min (Figure1). The mean 248 
plasma BHBA concentration reached and maintained was 1.7 ± 0.1 mmol/L for 48 h.  249 
The infusion of BHBA resulted in a marked increase in plasma BHBA concentration in 250 
HyperB cows (P < 0.001). Plasma BHBA concentration in control cows remained unchanged. 251 
Consequently, larger AUC was observed (Table 2) for plasma BHBA concentration in 252 
HyperB (1.74 ± 0.02 mmol/L, mean ± SEM) cows compared with the control cows (0.59 ± 253 
0.02 mmol/L) on d2 (P < 0.001).  254 
 255 
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Feed intake, energy balance, and ECM 256 
Dry matter intake (DMI) of hay and concentrate prior to the infusions (d0) is shown in table 3. 257 
On day 1 of the infusions, DMI of hay and concentrate was 19.1 ± 0.4 kg/d, and 16.9 ± 1.9 258 
kg/d, for HyperB, and control cows, respectively. On day 2 of the infusions, DMI of hay and 259 
concentrate was 19.0 ± 0.9 kg/d, and 17.9 ± 1.0 kg/d, for HyperB, and control cows, 260 
respectively. The DMI was not affected by BHBA infusion.  261 
The nutritive energy balance was remained unaffected by HyperB and similar in both groups 262 
across the study period. The change from d0 to d2 (delta), was -1.04 ± 8.67MJ/d, and 1.72 ± 263 
4.9 MJ/d for HyperB and control cows, respectively. Milk yield and ECM were not affected 264 
by BHBA infusion. 265 
 266 
Blood metabolites and enzymes 267 
Plasma glucose concentration in HyperB cows decreased (P = 0.03, Table 4) and was lower 268 
compared with control group on d2 (P = 0.0012, Table 2) (Figure 2). Beta-hydroxybutyrate 269 
infusion decreased the plasma glucagon concentration on day 2 (P = 0.03) (Figure 3). Plasma 270 
concentrations of NEFA, IGF-1, Urea, triglyceride (TG), Cortisol, and Insulin (Figure 4) 271 
remained unchanged in both HyperB and control groups during the course of infusion. The 272 
plasma Urea, IGF-1, and TG decreased within control group, and the plasma glucose and urea 273 
decreased within HyperB group. 274 
 275 
Liver gene expression 276 
The mRNA abundance in liver of the most studied variables did not differ between treatments 277 
(Table 5). Beta-hydroxybutyrate infusion affected on mRNA abundance of PRKAA1, and it 278 
tended to lower in HyperB group than the control group (P=0.08). The mRNA abundance of 279 
PC increase and that of PDHA1, and HMGCS1 decreased (P<0.05) over time within the 280 
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control cows. In the HyperB group the mRNA abundance of HMGCS1 decreased 281 
significantly over time. 282 
 283 
DISCUSSION 284 
Our objective was to induce an elevated plasma concentration of BHBA without the 285 
metabolic situation as observed during the early lactation, to solely investigate the effect of 286 
BHBA on feed intake, milk yield, and metabolism. This study is to the best of our knowledge 287 
the first one that induced an elevated plasma BHBA concentration for 48 h in dairy cows by 288 
infusion of BHBA. Plasma BHBA concentration reached was 1.7 ± 0.1 mmol/L, which was 289 
clearly above the mostly considered concentration of 1.2 to 1.4 mmol/L referring to 290 
subclinical ketosis (Duffield et al., 2009; Ospina et al., 2010). 291 
The expected reduction of DMI in HyperB cows as shown in cows with spontaneously 292 
elevated ketone body concentrations (Bareille et al., 2003; Gonzàlez et al., 2008) was not 293 
observed in our study. Subcutaneous injection of BHBA (10 mmol/kg body weight) in rats 294 
(Langhans et al., 1983; Moor et al., 1976), intraperitoneally BHBA infusion (15 mmol/kg
0.75
) 295 
in pigmy goats (Rossi et al., 2000), and intracerebroventricular BHBA infusion (18mM/d) in 296 
dairy cow (Kohla, 2011) decreased feed intake. Beta-hydroxybutyrate can play a role in 297 
regulation of feed intake (Langhans, 1983). In an in vitro experiment, elevation of BHBA: 298 
glucose ratio to 1:1 in early lactation compare with non-ketotic cows with a 1:4 ratio, can 299 
decrease feed intake via stimulation of dephosphorylation of AMPK after parturition (Laeger 300 
et al, 2012). In our study, BHBA infusion did not affect feed intake throughout the experiment 301 
which may relate to low ratio of BHBA: glucose. 302 
During the experiment plasma glucose concentration decreased dramatically due to the 303 
infusion of BHBA. This finding is consistent with other reports of decreased plasma glucose 304 
concentration associated with elevated BHBA in pregnant sheep (Schlumbohm and Harmyer 305 
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2003, 2004), dogs (Madison et al., 1964; Felts et al., 1964), and pigs (Müller et al, 1984). 306 
However, our findings are in contrast to other reports that described a hyperglycemia in 307 
rabbits (Mirsky and Broh- Kahn, 1937; Caccuri, 1937) induced by ketone bodies infusion. 308 
Information about the reasons for decreased plasma glucose concentration due to the elevated 309 
BHBA concentration is limited. Hypothetically, insulin plays a role in this effect. Infusion of 310 
BHBA increases insulin secretion in pigs (Müller 1984). Madison et al (1964) suggested that 311 
pancreatic beta cells respond to the high plasma BHBA concentration with increased insulin 312 
secretion in dogs. It appears that insulin suppresses the glucose production throughout an 313 
inhibitory effect on the regulatory enzymes of gluconeogenesis (Hayirli, 2006; Brockman and 314 
Larveld, 1986). This release of endogenous insulin can lead to decline in plasma glucose 315 
concentration, and reduce the hepatic glucose production. The unchanged insulin 316 
concentration in response to the BHBA infusion in the present study may be explained by the 317 
fact that ketone bodies represent only a modest stimulus on insulin secretion in ruminant 318 
(Jordan and Philips, 1978; Heitman and Fernandez, 1986). Insulin did obviously not play a 319 
significant role in mediating the lowering effect of BHBA on plasma glucose concentration in 320 
sheep (Schlumbohm and Harmyer 2003). Decreased glucose concentration and hepatic 321 
glucose output due to the infusion of BHBA can reduce the availability of glucose for the 322 
peripheral tissues because exhausted glucose stores must be replaced by a catabolism of 323 
proteins during emergency conditions for the vital tissues such as central nervous system 324 
(Madison et al., 1964). The molarity of ketone bodies in plasma are the same or higher than 325 
that of glucose. Thus, enhanced plasma BHBA concentration can increase the efficiency of 326 
BHBA as a competitor to glucose used by peripheral tissues and has been shown to inhibit 327 
peripheral glucose utilization (Madison et al., 1964). Ketone bodies are a preferred energy 328 
source by body tissues compared to glucose, because 100 g of BHBA produces 10.5 kg ATP 329 
whereas 100 g glucose produces 8.7 kg ATP (Salway 1999). Mebane et al (1962) 330 
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demonstrated that ketone body infusion leads to a 30% reduction in glucose utilization by 331 
peripheral tissues. Previous studies also reported that the oxidation of glucose was inhibited 332 
by ketone body infusion (Neptune et al., 1961; Williamson and Krebs, 1961). In contrast, as 333 
above mentioned Schlumbohm and Harmyer (2004) suggested that BHBA infusion decreased 334 
endogenous glucose production but did not affect glucose utilization in pregnant sheep. 335 
Furthermore they suggested that the elevated concentration of ketone bodies in blood initially 336 
decline glucose production via the depressed signal on hepatic gluconeogenesis in liver. 337 
In contrast to a previous study that found increased glucagon concentrations after BHBA 338 
infusion in pigs (Müller 1984), in our study BHBA infusion decreased glucagon concentration 339 
in HyperB compared with the control group. Plasma glucose is derived from the feed, 340 
glycogen, and by gluconeogenesis, and it is regulated by several hormones, mainly glucagon 341 
and insulin. Glucagon increases plasma glucose concentration through stimulation of 342 
gluconeogenesis and glycogenolysis (Aronoff et al, 2004; Grald and Taborsky, 2010). Change 343 
in glucagon secretion from the physiological range results in changes of plasma glucose 344 
concentration (Grald and Taborsky, 2010). Some substrates such as NEFA and ketone bodies 345 
suppress glucagon secretion (Gerich et al., 1974; Gerich et al., 1976; Goberna et al., 1974). 346 
There is evidence that glucagon secretion is inhibited by the neighboring β- cell through 347 
insulin (Weir et al, 1976) and gamma amino butyric acid (GABA) (Adeghate et al., 2000; 348 
Wendt et al., 2004). Gamma amino butyric acid is an inhibitory neurotransmitter in the brain. 349 
In an in vitro study it was demonstrated that BHBA increase GABA concentration in the 350 
epileptic brain (Suzuki et al., 2009). We suspect that the decrease in glucagon concentration in 351 
our study is related to elevated BHBA concentration as BHBA is used as an alternative fuel 352 
and energy source for the tissues, or glucagon secretion was prevented by the GABA 353 
inhibitory effect. Subsequently a decline of glucagon secretion decreased glucose production 354 
through the effect on glycogenolysis or gluconeogenesis during the experiment.  355 
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We have expected a decrease of plasma NEFA concentration in response to the BHBA 356 
infusion and a subsequent increase of insulin (Madison et al., 1964), both variables did not 357 
change during the experimental period.  358 
Beta-hydroxybutyrate can replace glucose to be utilized in peripheral tissues (Madison et al., 359 
1964), and this can help to decline fatty acid mobilization from adipose tissues. On the other 360 
hand after a decline in glucose concentration and subsequently NEB, enhance of NEFA 361 
occurred in early lactation (van Dorland et al., 2009), but in this study despite of decreased 362 
glucose, cows were not in the NEB situation. Although liver is the main site to produce 363 
ketone bodies from fatty acid oxidation, it cannot utilize the ketone bodies for the synthesis of 364 
acetoacetyl CoA and subsequently fatty acids due to a lack of the Succinyl-CoA:3-ketoacid-365 
coenzyme A transferase 1, mitochondrial (OXCT1), (Goodridge and Sul,, 2000). 366 
 367 
Effects of BHBA infusion on hepatic gene expression 368 
Our results of mRNA abundance of key enzymes related to hepatic gluconeogenesis (pyruvate 369 
carboxylase, glucose-6-phosphatase, mitochondrial phosphoenolpyruvate carboxykinase) are 370 
in contrast with suggestions from previous studies that indicated an inhibition of 371 
gluconeogenesis by elevated plasma BHBA concentration (Schlumbohm and Harmyer, 2003; 372 
Müller 1984). Müller et al (1984) suggested that ketone bodies probably have a direct 373 
inhibitory action on gluconeogensis. They mentioned that the effect of ketone bodies on 374 
endogenous glucose production is probably mediated by insulin. However, in ruminants the 375 
effect of ketone bodies on insulin secretion is not strong (Jordan and Philips, 1978; Heitman 376 
and Fernandez, 1986), and insulin concentration did not change in our study. Soling and 377 
Kleineke (1976) suggested that ketone bodies have a glucose sparing effect in tissues through 378 
mitochondrial formation of citrate, an allosteric inhibitor, phosphofructo-1,6-kinase, acetyl- 379 
CoA inhibition of pyruvate dehydrogenase and activation of pyruvate carboxylase. Beta-380 
hydroxybutyrate infusion did not affect on key enzymes related to gluconeogensis, glycolysis, 381 
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pyruvate dehydrogenase complex (PDH complex), and citrate synthase mRNA expression. 382 
According to the mRNA abundance of some enzymes related to fatty acid oxidation, BHBA 383 
infusion did not affect fatty acid oxidation. These results are not in agreement with previous 384 
reports (Soling and Kleineke, 1976; Morio and Wolfe, 2005) that mentioned ketone bodies are 385 
an inhibitor for fatty acid oxidation through increase acetyl CoA production, inhibit CPT1 386 
activity, and stimulate malonyl CoA synthesis. 387 
As mentioned above ketone bodies suppressed the glucagon secretion, and this inhibition 388 
could have been regulated via cAMP. The mechanism of this inhibition is related to the 389 
generation of ATP/ADP by substrate such as ketone bodies, then decrease of cAMP and 390 
finally prevention of glucagon secretion (Gerich et al., 1976; Toyota et al., 1975; Mitrakou et 391 
al., 1991; Adeghate et al., 2000). In the present study, the PRKAA1 expression tended to 392 
decrease in HyperB compared with control group (P<0.1). On the other hand, BHBA infusion 393 
decreased the PRKAA1 expression, subsequently glucagon excretion was decreased.  394 
 395 
CONCLUSION 396 
Results from this study demonstrate that intravenous BHBA infusion successfully induced 397 
elevated plasma BHBA concentration for a long term (48 h) in dairy cows. Based on this 398 
study feed intake is not affected by elevated BHBA concentration during a period positive 399 
energy balance. Decreased plasma glucose concentration during BHBA administration cannot 400 
be related to changes of insulin concentration or to mRNA abundance of genes related to 401 
hepatic gluconeogenesis, fatty acid synthesis, citrate synthase, pyruvate dehydrogenase 402 
complex, and glycolysis. Although mRNA expression indicated high activity of enzyme 403 
production, the effects of BHBA infusion occurred most likely at a post-transcriptional level. 404 
Reduced glucose concentration maybe related to decrease in plasma glucagon concentration 405 
17 
 
which can decrease glucose production from gluconeogenesis or glycogen storage. Thus 406 
BHBA seems to have a glucose sparing effect. However, glucose entry rate was probably 407 
reduced by the treatment, and additional studies will be necessary to clarify the underlying 408 
mechanisms.  409 
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Figure legends 
 
Figure 1. Beta-hydroxybutyrate (BHBA) infusion rate during 48 h infusion in BHBA 
cows (HyperB). Plasma BHBA concentration in control cows and cows 
infused with BHBA before the start of the infusion (d0) and during 48 h 
infusion. Values represent Mean ± SEM. 
 
Figure 2. Plasma glucose concentration in control cows and cows infused with BHBA 
before the start of the infusion (d0) and during 48 h infusion. Values represent 
Mean ± SEM. 
 
Figure 3. Plasma glucagon concentration in control cows and cows infused with BHBA 
before the start of the infusion (d0) and during 48 h infusion. Values represent 
Mean ± SEM.   
 
Figure 4. Plasma insulin concentration in control cows and cows infused with BHBA 
before the start of the infusion (d0) and during 48 h infusion. Values represent 
Mean ± SEM. 
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Plasma glucagon concentration
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Table 1. Polymerase chain reaction primer information (for = forward, rev = reverse), annealing temperature 
and the PCR product length 
Gene
1
 Sequence 5’-3’ 
Gene Bank  
accession no. 
Annealing  
temperature 
(°C) 
Length,
bp 
Gluconeogenesis related variables 
G6PC 
for GCCAACCTACAGATTTCGGTG 
NM-001076124 58 140 
rev CAATGCCTGACAAGACTCCAG 
PC 
for ATCTCCTACACGGGTGACGT 
NM_177946 60 214 
rev TGTCGTGGGTGTGGATGTGCA 
PEPCKm 
for TACGAGGCCTTCAACTGGCGT 
XM_583200 60 365 
rev AGATCCAAGGCGCCTTCCTTA 
Phosphofructokinase ,liver and lactate dehydrogenase 
LDHA 
for CGGTTCACAAACAAGTGGTTG 
NM-174099 60 166 
rev GAGACCCTTAATCATGGTGG 
LDHB 
for CAGCATTCTGGGAAAGTCTC 
NM-174100 60 141 
rev GAGTAATCTTTGTCTGCCAC 
PFKL 
for TTGACTGCAGGACCAACGTC 
NM-001080244 60 120 
rev GCAGCTTCTCCGACATCCAG 
Glucagon receptor, glycogen synthase, protein kinase, AMP- activated alpha 1  
GCGR 
for TCCCAGTGTCAGATGGATGA 
NM-001192414 60 207 
rev CTTGAGCATGAAGGACACGA 
GYS2 
for AAACTTCCTGCTGAGGATGC 
NM-001192905 58 138 
rev GAATGTGCAGTGTCCCATAG 
PRKAA1 
for AAACTGTACCAGGTCATCAG 
NM-001109802 58 326 
rev GAAATTACTTCTGGTGCAGC 
Pyruvate dehydrogenase complex variables 
DBT 
for GTCGCCTTGCAATGGAAAAC 
NM-173905 60 248 
rev GTGAAAGCCTTTCACGGGTTC 
DLD 
for TGGTCAAGAGAGGCCATTTC 
NM-001206170 60 16 
rev AACTGGGCAGCTTTAATAGC 
PDHA1 
for ACACAGCATGAGTGATCCTG 
NM-001101046 60 127 
rev CTTCAACACTGGCGAGATTG 
Fatty acid and cholesterol synthesis related variables 
ACOAC 
for CTCTTCCGACAGGTTCAAGC 
AJ-132890 61 248 
rev ACCATCCTGGCAAGTTTCAC 
FASN 
for CTGAGTCGGAGAACCTGGAG 
NM_001012669 63 232 
rev ACAATGGCCTCGTAGGTGAC 
HMGCS1 
for TGTACGGCTCCCTGGCTTCTG 
BC-102850 60 313 
rev CATGTTCCTTCGAAGAGGGAATC 
Fatty acid oxidation related variables 
ACSL1 
for TGACTGTTGCTGGAGACTGG 
NM-001076085 61 199 
rev CAGCCGTCTTTATCCAGAGC 
CPT1 
for CAAAACCATGTTGTACAGCTTCCA 
BF039285 54 111 
rev GCTTCCTTCATCAGAGGCTTCA 
CPT2 
for CAGCCTGCCCAGGCTGCCTAT 
BC105423 60 163 
rev AGTGACCAGCTGCTCATGCA 
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Citrate synthase, and ketogenesis related variables 
CS 
for TGGACATGATGTATGGTGG 
BC-114138 60 217 
rev AGCCAAGATACCTGTTCCTC 
HMGCS2 
for TCTGGCCCATCACTCTGCC 
NM-001045883 60 126 
rev AGTGGGGAGCCTGGAGAAGC 
1
ACoAC = acetyl-CoA carboxylase; ACSL1 = acyl-CoA synthetase long-chain; CPT1A = carnitine 
palmitoyltransferase 1A; CPT2 = carnitine palmitoyltransferase 2; CS = citrate synthase; DBT = 
dihydrolipoamide branched chain transacylase E2; DLD = Dihydrolipoamide dehydrogenase; 
FASN= fatty acid synthase; G6PC = glucose-6-phosphatase; GCGR= glucagon receptor; GYS2= 
glycogen synthase 2; HMGCS1 = 3- hydroxyl-3 – methylglutaryl-coenzyme A synthase 1; HMGCS2 
= 3- hydroxyl-3 – methylglutaryl-coenzyme A synthase 2 ; LDHA = lactate dehydrogenase A; 
LDHB = lactate dehydrogenase B; PC = pyruvate carboxylase; PDHA1 = pyruvatedehydrogenase 
(lipomide) alpha 1; PEPCKm = mitochondrial phosphoenolpyruvate carboxykinase; PFKL = 
phosphofructokinase,liver; PPKA1= protein kinase, AMP- activated alpha 1. 
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Table 2. Least square means ± SEM of area under the curve (AUC) Plasma variables concentration in dairy 
cows infused with beta-hydroxybutyrate (HyperB) or saline (NaCl) on day 2.
 
 
1
BHBA= Beta-hydroxybutyrate; INS= Insulin; NEFA= non-esterified fatty acids; IGF-1= Insulin Growth 
Factor-1; TG= Triglyceride 
2 
HyperB= Hyper beta hydroxybutyrate group; NaCl= group of cows receiving physiological saline solution
  
 
 
 
 
 
 
 
 
 
 
 
 
Variable
 1 
Group
2 LSMeans ± SEM 
day 2 
ANOVA 
 (P-Value, group) 
Glucose, mmol/L 
HyperB 3.47 ± 0.11 
< 0.01 
NaCl 4.11 ± 0.08 
INS, mU/L 
HyperB 12.7 ± 1.4 
0.54 
NaCl 13.9 ± 1.1 
BHBA, mmol/L 
HyperB 1.74 ± 0.02 
< 0.001 
NaCl 0.59 ± 0.02 
NEFA, mmol/L 
HyperB 0.06 ± 0.03 
0.51 
NaCl 0.09 ± 0.02 
Urea, mmol/L 
HyperB 3.77 ± 0.31 
0.63 
NaCl 3.97 ± 0.24 
Glucagon, pg/ml 
HyperB 97.4 ± 3.3 
< 0.05 
NaCl 107.7 ± 2.6 
IGF-1, ng/mL 
HyperB 90 ± 4.5 
0.11 
NaCl 80 ± 3.6 
TG, mmol/L 
HyperB 0.15 ± 0.01 
0.58 
NaCl 0.14 ± 0.01 
Cortisol, ng/mL 
HyperB 2.41 ± 0.55 
0.78 
NaCl 2.62 ± 0.43 
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Table 3. Milk yield, ECM, DMI, and Energy balance of dairy cows infused with beta-hydroxybutyrate 
(HyperB) or saline (NaCl) before the start of the infusion (d0) and difference (delta: d2-d0) between before 
and after 48h infusion(d2). Values represent Mean ± SEM.  
 
1 
DMI= dry matter intake; ECM= energy corrected milk; EB= energy balance;  
2 
HyperB= Hyper beta-hydroxybutyrate group; NaCl= cow group receiving physiological saline solution 
*
Delta is different from 0 (P < 0.05) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable
 1 
Group
2 
d0 
Delta 
d2-d0 
ANOVA 
 (P-Value, group) 
Milk yield, Kg/day 
HyperB 23.31 ± 0.78 -3.30 ± 1.43* 
0.3 
NaCl 21.78 ± 2.53 -1.76 ± 0.68 
        
ECM, Kg/day 
HyperB 21.00 ± 0.28 -1.58 ± 0.76
 
0.79 
NaCl 21.95 ± 2.58 -1.21 ± 0.85 
        
DMI, Kg/day 
HyperB 19.82 ± 0.66 -0.80 ± 1.22 
0.76 
NaCl 18.33 ± 1.28 -0.38 ± 0.76 
        
EB, MJ/d 
HyperB 15.04 ± 2.18 -1.04 ± 8.67
 
0.77 
NaCl 1.67 ± 4.90 1.72 ± 4.90 
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Table 4. Plasma variables concentrations in dairy cows infused with beta-hydroxybutyrate (HyperB) or saline 
(NaCl) before the start of the infusion (d0) and difference (delta: d2-d0) between before and after 48h infusion 
(d2). Values represent Mean ± SEM. 
 
1
BHBA= Beta-hydroxybutyrate; INS= Insulin; NEFA= non-esterified fatty acids; IGF-1= Insulin Growth 
Factor-1; TG= Triglyceride 
2 
HyperB= Hyper beta-hydroxybutyrate group; NaCl= cow group receiving physiological saline solution 
*
Delta is different from 0 (P < 0.05) 
 
 
 
 
 
 
 
Variable
 1 
Group
2 
d0 
Delta 
d2-d0 
ANOVA 
 (P-Value, group) 
Glucose, mmol/L 
HyperB 4.10 ± 0.08 -0.46 ± 0.18* 
< 0.05 
NaCl 3.87 ± 0.08 0.10 ± 0.14 
        
INS, mU/L 
HyperB 8.74 ± 0.78 -1.56 ± 0.92 
0.30 
NaCl 6.78 ± 1.62 0.14 ± 1.08 
        
BHBA, mmol/L 
HyperB 0.51 ± 0.05 0.74 ± 0.15* 
< 0.001 
NaCl 0.42 ± 0.04 0.09 ± 0.05 
        
NEFA, mmol/L 
HyperB 0.11 ± 0.02 -0.02 ± 0.02 
0.7 
NaCl 0.16 ± 0.03 -0.04 ± 0.04 
        
Urea, mmol/L 
HyperB 4.73 ± 0.34 -1.25 ± 0.3*
 
0.73 
NaCl 5.0 ± 0.26 -1.05 ± 0.4*
 
        
IGF-1, ng/mL 
HyperB 91 ± 6.1 -6.65 ± 2.5 
0.55 
NaCl 100 ± 10.0 -9.87 ± 3.7*
 
        
Glucagon, pg/ml 
HyperB 115.2 ± 19.1 -17.3 ± 1.3*
 
0.06 
NaCl 109.6 ± 5.4 -1.0 ± 6.1 
      
 
 
TG, mmol/L 
HyperB 0.18 ± 0.01 -0.02 ± 0.01 
0.91 
NaCl 0.16 ± 0.01 -0.02 ± 0.01*
 
        
Cortisol,  ng/mL 
HyperB 5.74 ± 1.4 -2.37 ± 1.9 
0.67 
NaCl 2.92 ± 0.8 -1.56 ± 0.9 
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Table 5. Liver mRNA expression in dairy cows infused with beta-hydroxybutyrate (HyperB) or saline (NaCl) 
before the start of the infusion (d0) and difference (delta: d2-d0) between before and after 48h infusion (d2). 
Values represent Mean ± SEM. 
Variable
 1 
Group
2 
d0 
Delta 
d2-d0 
ANOVA 
 (P-Value, 
group) 
Gluconeogenesis related  variables 
G6PC 
HyperB 22.89 ± 0.46 -0.57 ± 0.50 
0.44 
NaCl 21.05 ± 0.49 -0.18 ± 0.24 
PC 
HyperB 17.42 ± 0.22 0.43 ± 0.08 
0.87 
NaCl 17.57 ± 0.13 0.48 ± 0.23
*
 
PEPCKm 
HyperB 14.60 ± 0.43 0.46 ± 0.29 
0.18 
NaCl 14.85 ± 0.20 -0.21 ± 0.32 
Phosphofructokinase ,liver and lactate dehydrogenase 
LDHA 
HyperB 16.58 ± 0.22 -0.58 ± 0.32 0.80 
NaCl 16.50 ± 0.30 -0.45 ± 0.34  
LDHB 
HyperB 19.47 ± 0.32 0.01 ± 0.18 0.52 
NaCl 19.68 ± 0.38 -0.36 ± 0.45
 
 
PFKL 
HyperB 15.00 ± 0.25 0.35 ± 0.37 0.35 
NaCl 15.38 ± 0.21 -0.22 ± 0.40  
Glucagon receptor, glycogen synthase, protein kinase, AMP- activated alpha 1 
GCGR 
HyperB 17.92 ± 0.19 -0.33 ± 0.24 
0.91 
NaCl 16.98 ± 0.56 -0.24 ± 0.28 
GYS2 
HyperB 19.03 ± 0.28 -0.90 ± 0.35 
0.83 
NaCl 17.56 ± 0.49 -0.57 ± 0.29 
PRKAA1 
HyperB 15.19 ± 0.22 -0.57 ± 0.30 
0.08 
NaCl 14.11 ± 0.36 0.11 ± 0.21 
Pyruvate dehydrogenase complex  variables 
DBT 
HyperB 18.19 ± 0.18 -0.09 ± 0.23 
0.90 
NaCl 17.64 ± 0.27 -0.21 ± 0.68 
DLD 
HyperB 18.14 ± 0.17 -0.52 ± 0.31 
0.84 
NaCl 17.90 ± 0.14 -0.38 ± 0.48 
PDHA1 
HyperB 17.94 ± 0.14 -0.58 ± 0.46 
0.53 
NaCl 18.09 ± 0.17 -1.03 ± 0.46
*
 
Fatty acid and cholesterol synthesis related  variables 
ACOAC 
HyperB 10.41 ± 0.18 -0.44 ± 0.34 
0.64 
NaCl 8.66 ± 0.51 -0.74 ± 0.43
 
FASN 
HyperB 14.0 ± 0.4 -0.8 ± 0.3 
0.82 
NaCl 14.0 ± 0.51 -0.9 ± 0.5 
HMGCS1 
HyperB 20.95 ± 0.24 -1.61 ± 0.51* 
0.69 
NaCl 18.84 ± 0.46 -1.24 ± 0.60* 
Fatty acid oxidation related  variables 
ACSL 
HyperB 19.76 ± 0.17 0.05 ± 0.19 
0.65 
NaCl 18.87 ± 0.49 -0.07 ± 0.16 
CPT1 
HyperB 14.82 ± 0.22 -0.28 ± 0.29 
0.55 
NaCl 13.16 ± 0.36 -0.09 ± 0.16 
CPT2 
HyperB 18.07 ± 0.12 -0.33 ± 0.10 
0.54 
NaCl 17.19 ± 0.29 -0.46 ± 0.14 
Citrate synthase, and ketogenesis related  variables 
CS 
HyperB 14.48 ± 0.06 -0.26 ± 0.15 
0.91 
NaCl 12.77 ± 0.40 -0.23 ± 0.20 
HMGCS2 
HyperB 21.62 ± 0.33 -0.23 ± 0.33 
0.77 
NaCl 21.14 ± 0.32 -0.10 ± 0.29 
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1
ACoAC = acetyl-CoA carboxylase; ACSL1 = acyl-CoA synthetase long-chain; CPT1A = carnitine 
palmitoyltransferase 1A; CPT2 = carnitine palmitoyltransferase 2; CS = citrate synthase; DBT = 
dihydrolipoamide branched chain transacylase E2; DLD = Dihydrolipoamide dehydrogenase; 
FASN= fatty acid synthase; G6PC = glucose-6-phosphatase; GCGR= glucagon receptor; GYS2= 
glycogen synthase 2; HMGCS1 = 3- hydroxyl-3 – methylglutaryl-coenzyme A synthase 1; HMGCS2 
= 3- hydroxyl-3 – methylglutaryl-coenzyme A synthase 2 ; LDHA = lactate dehydrogenase A; 
LDHB = lactate dehydrogenase B; PC = pyruvate carboxylase; PDHA1 = pyruvatedehydrogenase 
(lipomide) alpha 1; PEPCKm = mitochondrial phosphoenolpyruvate carboxykinase; PFKL = 
phosphofructokinase,liver; PPKA1= protein kinase, AMP- activated alpha 1. 
2 
HyperB= Hyper beta-hydroxybutyrate group; NaCl= cow group receiving physiological saline 
solution 
*
Delta is different from 0 (P < 0.05) 
